Why Almost Everything You Hear about Medicine Is Wrong
Begley, Sharon, Newsweek
Byline: Sharon Begley
If you follow the news about health research, you risk whiplash. First garlic lowers bad cholesterol, then--after more study--it doesn't. Hormone replacement reduces the risk of heart disease in postmenopausal women, until a huge study finds that it doesn't (and that it raises the risk of breast cancer to boot). Eating a big breakfast cuts your total daily calories, or not--as a study released last week finds. Yet even if biomedical research can be a fickle guide, we rely on it.
But what if wrong answers aren't the exception but the rule? More and more scholars who scrutinize health research are now making that claim. It isn't just an individual study here and there that's flawed, they charge. Instead, the very framework of medical investigation may be off-kilter, leading time and again to findings that are at best unproved and at worst dangerously wrong. The result is a system that leads patients and physicians astray--spurring often costly regimens that won't help and may even harm you.
It's a disturbing view, with huge im-plications for doctors, policymakers, and health-conscious consumers. And one of its foremost advocates, Dr. John P.A. Ioannidis, has just ascended to a new, prominent platform after years of crusading against the baseless health and medical claims. As the new chief of Stanford University's Prevention Research Center, Ioannidis is cementing his role as one of medicine's top mythbusters. "People are being hurt and even dying" because of false medical claims, he says: not quackery, but errors in medical research.
This is Ioannidis's moment. As medical costs hamper the economy and impede deficit-reduction efforts, policymakers and businesses are desperate to cut them without lowering sacrificing sick people. One no-brainer solution is to use and pay for only treatments that work. But if Ioannidis is right, most biomedical studies are wrong.
In just the last two months, two pillars of preventive medicine fell. A major study concluded there's no good evidence that statins (drugs like Lipitor and Crestor) help people with no history of heart disease. The study, by the Cochrane Collaboration, a global consortium of biomedical experts, was based on an evaluation of 14 individual trials with 34,272 patients. Cost of statins: more than $20 billion per year, of which half may be unnecessary. (Pfizer, which makes Lipitor, responds in part that "managing cardiovascular disease risk factors is complicated"). In November a panel of the Institute of Medicine concluded that having a blood test for vitamin D is pointless: almost everyone has enough D for bone health (20 nanograms per milliliter) without taking supplements or calcium pills. Cost of vitamin D: $425 million per year.
Ioannidis, 45, didn't set out to slay medical myths. A child prodigy (he was calculating decimals at age 3 and wrote a book of poetry at 8), he graduated first in his class from the University of Athens Medical School, did a residency at Harvard, oversaw AIDS clinical trials at the National Institutes of Health in the mid-1990s, and chaired the department of epidemiology at Greece's University of Ioannina School of Medicine. But at NIH Ioannidis had an epiphany. "Positive" drug trials, which find that a treatment is effective, and "negative" trials, in which a drug fails, take the same amount of time to conduct. "But negative trials took an extra two to four years to be published," he noticed. "Negative results sit in a file drawer, or the trial keeps going in hopes the results turn positive." With billions of dollars on the line, companies are loath to declare a new drug ineffective. As a result of the lag in publishing negative studies, patients receive a treatment that is actually ineffective. That made Ioannidis wonder, how many biomedical studies are wrong?
His answer, in a 2005 paper: "the majority." From clinical trials of new drugs to cutting-edge genetics, biomedical research is riddled with incorrect findings, he argued. …